OCRF & Ovarian Cancer National Alliance are now one strong, united, inspiring voice!
Ovarian Cancer Research Fund (OCRF) and the Ovarian Cancer National Alliance (OCNA) have led the way in advocacy, research and support for patients and their families for over 22 years. As of January 2016, we are pleased to announce we are joining together to form Ovarian Cancer Research Fund Alliance (OCRFA), the largest global organization dedicated to advancing ovarian cancer research while supporting women and their families. Read the exciting news!


Avastin and Chemo for Platinum-Resistant Ovarian Cancer Increases Progression Free Survival

(March 20, 2014) A group of French researchers conducted a randomized, phase III trial (called AURELIA) combining bevacizumab (Avastin) with chemotherapy in platinum-resistant ovarian cancer.  The results of the trial, which enrolled 361 patients, were published in the Journal of Clinical Oncology.

The primary end point was progression-free survival (PFS). Secondary end points included objective response rate (ORR), overall survival (OS), safety, and patient-reported outcomes.

For those that were randomized into combination therapy (chemotherapy plus bevacizumab), progression free survival increased from 3.4 months with chemotherapy along versus 6.7 months with bevacizumab-containing therapy.   ORR was 11.8% versus 27.3%, respectively.

Adding bevacizumab to chemotherapy statistically significantly improved PFS and ORR; the OS trend was not significant.

Click here for the abstract;  click here to hear a podcast explaining these findings.